After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth
Executive Summary
Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.
You may also be interested in...
Life Without Plavix: Sanofi Highlights Next Generation Drugs
Sanofi will lose exclusivity for Plavix, Avapro and Eloxatin in 2012, driving what it expects will be a 12% to 15% EPS decline, but management is counting on a new wave of drugs – and the addition of Genzyme – to return to growth.
Sanofi Targets 18 Drug Launches From 2012 To 2015
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
Sanofi Targets 18 Drug Launches From 2012 To 2015
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.